Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2025 08:00 ET | Source: Vaxart, Inc.

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
April 30, 2025 16:05 ET | Source: Vaxart, Inc.

Vaxart to Present at the Citizens Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that members of the management team will present at the Citizens Life Sciences conference...
April 30, 2025 08:00 ET | Source: Vaxart, Inc.

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

- Topline data expected in mid-2025 - SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1...
April 16, 2025 08:00 ET | Source: Vaxart, Inc.

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief...
March 27, 2025 08:00 ET | Source: Vaxart, Inc.

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on March 24, 2025, the independent members of the Board...
March 20, 2025 16:01 ET | Source: Vaxart, Inc.

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19...
March 13, 2025 08:00 ET | Source: Vaxart, Inc.

Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
March 11, 2025 08:00 ET | Source: Vaxart, Inc.

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label,...
March 05, 2025 16:05 ET | Source: Vaxart, Inc.

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that complete data from the Phase 1b trial of its first-generation oral pill norovirus...
January 28, 2025 08:00 ET | Source: Vaxart, Inc.

Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

Mr. Finney brings 35 years of leadership, operations and corporate development experience SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company”...